Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
1.
FASEB J ; 31(12): 5440-5452, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28842432

RESUMEN

NAD+ depletion is a common phenomenon in neurodegenerative pathologies. Excitotoxicity occurs in multiple neurologic disorders and NAD+ was shown to prevent neuronal degeneration in this process through mechanisms that remained to be determined. The activity of nicotinamide riboside (NR) in neuroprotective models and the recent description of extracellular conversion of NAD+ to NR prompted us to probe the effects of NAD+ and NR in protection against excitotoxicity. Here, we show that intracortical administration of NR but not NAD+ reduces brain damage induced by NMDA injection. Using cortical neurons, we found that provision of extracellular NR delays NMDA-induced axonal degeneration (AxD) much more strongly than extracellular NAD+ Moreover, the stronger effect of NR compared to NAD+ depends of axonal stress since in AxD induced by pharmacological inhibition of nicotinamide salvage, both NAD+ and NR prevent neuronal death and AxD in a manner that depends on internalization of NR. Taken together, our findings demonstrate that NR is a better neuroprotective agent than NAD+ in excitotoxicity-induced AxD and that axonal protection involves defending intracellular NAD+ homeostasis.-Vaur, P., Brugg, B., Mericskay, M., Li, Z., Schmidt, M. S., Vivien, D., Orset, C., Jacotot, E., Brenner, C., Duplus, E. Nicotinamide riboside, a form of vitamin B3, protects against excitotoxicity-induced axonal degeneration.


Asunto(s)
Axones/efectos de los fármacos , Axones/metabolismo , Niacinamida/análogos & derivados , Animales , Muerte Celular/efectos de los fármacos , Células Cultivadas , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , N-Metilaspartato/farmacología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Fármacos Neuroprotectores/farmacología , Niacinamida/farmacología , Compuestos de Piridinio , Reacción en Cadena en Tiempo Real de la Polimerasa
2.
FASEB J ; 27(12): 4712-22, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23975935

RESUMEN

In chronic degenerative syndromes, neuronal death occurs over long periods, during which cells progressively lose their axons and, ultimately, their cell bodies. Although apoptosis is recognized as a key event in neuronal death, the molecular mechanisms involved in CNS axons degeneration are poorly understood. Due to the highly polarized phenotypes of CNS neurons, the different neuronal subcompartments are likely to be targeted by light repetitive and localized aggression. Such locally initiated deleterious signal transduction pathways could theoretically spread through the cytoplasm. However, where axon-degenerative signals initiate, what these early signals are, and how they lead to axon degeneration are unanswered questions that limit our understanding of neurodegenerative diseases and our ability to identify novel therapeutic targets. Using a microfluidic culture device adapted to CNS primary neurons, allowing specific access to the axonal and somatodendritic compartments, we analyzed the molecular pathways involved in axonal degeneration of differentiated neurons. We show here that local application of proapoptotic stimuli on the somatodentritic compartment triggers a dying-back pattern involving caspase-dependent axonal degeneration. Using complementary pharmacological and genetic approaches, we further demonstrate that NAD(+) and grape wine polyphenols prevent axonal apoptosis and act via mitochondrial SirT3 activation in axons.


Asunto(s)
Apoptosis/efectos de los fármacos , Axones/metabolismo , Caspasas/metabolismo , NAD/farmacología , Sirtuina 3/metabolismo , Animales , Axones/efectos de los fármacos , Ratones , Microfluídica , Resveratrol , Estilbenos/farmacología
3.
Cogn Behav Neurol ; 25(3): 121-7, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22960436

RESUMEN

OBJECTIVE: To determine whether treatment with memantine plus vitamin D is more effective than memantine or vitamin D alone in improving cognition among patients with Alzheimer disease (AD). METHODS: We studied 43 white outpatients (mean 84.7 ± 6.3 years; 65.1% women) with a new diagnosis of AD, who had not taken anti-dementia drugs or vitamin D supplements. We prescribed memantine alone (n = 18), vitamin D alone (n = 17), or memantine plus vitamin D (n = 8) for an average of 6 months. We assessed cognitive change with the Mini-Mental State Examination (MMSE). We used age, sex, pre-treatment MMSE score, and duration of treatment as covariables. RESULTS: Before treatment, the 3 groups had comparable MMSE scores. At 6 months, participants taking memantine plus vitamin D increased their MMSE score by 4.0 ± 3.7 points (P = 0.034), while participants taking memantine alone remained stable (change of 0.0 ± 1.8 points; P = 0.891), as did those taking vitamin D alone (-0.6 ± 3.1 points; P = 0.504). Treatment with memantine plus vitamin D was associated with improvement in the MMSE score compared to memantine or vitamin D alone after adjustment for covariables (P < 0.01). Mixed regression analysis showed that the visit by combined treatments (memantine plus vitamin D) interaction was significant (P = 0.001), while memantine or vitamin D alone showed no effect. CONCLUSIONS: Patients with AD who took memantine plus vitamin D for 6 months had a statistically and clinically relevant gain in cognition, underlining possible synergistic and potentiating benefits of the combination.


Asunto(s)
Enfermedad de Alzheimer/complicaciones , Trastornos del Conocimiento/tratamiento farmacológico , Cognición/efectos de los fármacos , Memantina/uso terapéutico , Nootrópicos/uso terapéutico , Vitamina D/uso terapéutico , Anciano , Anciano de 80 o más Años , Trastornos del Conocimiento/complicaciones , Quimioterapia Combinada , Femenino , Humanos , Masculino , Memantina/farmacología , Pruebas Neuropsicológicas , Nootrópicos/farmacología , Proyectos Piloto , Resultado del Tratamiento , Vitamina D/farmacología
4.
Cells ; 11(23)2022 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-36497024

RESUMEN

In the heart, cardiac function is regulated by the autonomic nervous system (ANS) that extends through the myocardium and establishes junctions at the sinus node and ventricular levels. Thus, an increase or decrease in neuronal activity acutely affects myocardial function and chronically affects its structure through remodeling processes. The neuro-cardiac junction (NCJ), which is the major structure of this system, is poorly understood and only a few cell models allow us to study it. Here, we present an innovant neuro-cardiac organ-on-chip model to study this structure to better understand the mechanisms involved in the establishment of NCJ. To create such a system, we used microfluidic devices composed of two separate cell culture compartments interconnected by asymmetric microchannels. Rat PC12 cells were differentiated to recapitulate the characteristics of sympathetic neurons, and cultivated with cardiomyocytes derived from human induced pluripotent stem cells (hiPSC). We confirmed the presence of a specialized structure between the two cell types that allows neuromodulation and observed that the neuronal stimulation impacts the excitation-contraction coupling properties including the intracellular calcium handling. Finally, we also co-cultivated human neurons (hiPSC-NRs) with human cardiomyocytes (hiPSC-CMs), both obtained from the same hiPSC line. Hence, we have developed a neuro-cardiac compartmentalized in vitro model system that allows us to recapitulate the structural and functional properties of the neuro-cardiac junction and that can also be used to better understand the interaction between the heart and brain in humans, as well as to evaluate the impact of drugs on a reconstructed human neuro-cardiac system.


Asunto(s)
Células Madre Pluripotentes Inducidas , Humanos , Ratas , Animales , Células Madre Pluripotentes Inducidas/metabolismo , Sistemas Microfisiológicos , Miocitos Cardíacos/metabolismo , Miocardio/metabolismo , Calcio/metabolismo
5.
Cell Death Dis ; 13(11): 959, 2022 11 15.
Artículo en Inglés | MEDLINE | ID: mdl-36379916

RESUMEN

Caspase-2 (Casp2) is a promising therapeutic target in several human diseases, including nonalcoholic steatohepatitis (NASH) and Alzheimer's disease (AD). However, the design of an active-site-directed inhibitor selective to individual caspase family members is challenging because caspases have extremely similar active sites. Here we present new peptidomimetics derived from the VDVAD pentapeptide structure, harboring non-natural modifications at the P2 position and an irreversible warhead. Enzyme kinetics show that these new compounds, such as LJ2 or its specific isomers LJ2a, and LJ3a, strongly and irreversibly inhibit Casp2 with genuine selectivity. In agreement with the established role of Casp2 in cellular stress responses, LJ2 inhibits cell death induced by microtubule destabilization or hydroxamic acid-based deacetylase inhibition. The most potent peptidomimetic, LJ2a, inhibits human Casp2 with a remarkably high inactivation rate (k3/Ki ~5,500,000 M-1 s-1), and the most selective inhibitor, LJ3a, has close to a 1000 times higher inactivation rate on Casp2 as compared to Casp3. Structural analysis of LJ3a shows that the spatial configuration of Cα at the P2 position determines inhibitor efficacy. In transfected human cell lines overexpressing site-1 protease (S1P), sterol regulatory element-binding protein 2 (SREBP2) and Casp2, LJ2a and LJ3a fully inhibit Casp2-mediated S1P cleavage and thus SREBP2 activation, suggesting a potential to prevent NASH development. Furthermore, in primary hippocampal neurons treated with ß-amyloid oligomers, submicromolar concentrations of LJ2a and of LJ3a prevent synapse loss, indicating a potential for further investigations in AD treatment.


Asunto(s)
Enfermedad del Hígado Graso no Alcohólico , Peptidomiméticos , Humanos , Caspasa 2/metabolismo , Caspasa 3/metabolismo , Neuronas/metabolismo , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Peptidomiméticos/farmacología , Peptidomiméticos/metabolismo
6.
J Neurochem ; 104(5): 1321-32, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18005000

RESUMEN

Retinoid-related orphan receptor alpha1 (RORalpha1) is a member of the nuclear receptor superfamily. It is highly expressed in CNS particularly in the cerebellum. Absence of this transcription factor in mice leads to several abnormalities, such as cerebellar atrophy linked to Purkinje cell death and impaired differentiation. A major role of RORalpha1 in neuronal survival is the control of reactive oxygen species homeostasis. RORalpha1 is a constitutively active receptor, but its regulation is yet not well known. Protein kinase C (PKC) also plays a major role in neuronal survival and differentiation, suggesting its possible involvement in post-translational modifications and regulation of RORalpha1 transcriptional activity. To test this hypothesis, we over-expressed the human isoform of this nuclear receptor in cortical neurons and COS-7 cells, which were then treated with different effectors acting on PKC activity. We showed for the first time that conventional PKCs induce phosphorylation and inhibition of RORalpha1 activity. We also investigated mitogen-activated protein kinase/extracellular signal-regulated kinase (1/2) involvement in this effect. Our results bring new insights into the control of RORalpha1 activity and highlight its importance in further investigations of the mechanisms involved in neuronal cell death in neurodegenerative diseases.


Asunto(s)
Proteína Quinasa C/fisiología , Receptores Citoplasmáticos y Nucleares/metabolismo , Transactivadores/metabolismo , Transcripción Genética/fisiología , Animales , Células COS , Bovinos , Células Cultivadas , Chlorocebus aethiops , Humanos , Ratones , Neuronas/enzimología , Miembro 1 del Grupo F de la Subfamilia 1 de Receptores Nucleares , Fosforilación , Proteína Quinasa C/genética , Receptores Citoplasmáticos y Nucleares/genética , Transducción de Señal/genética , Transactivadores/genética
7.
Sci Rep ; 8(1): 11596, 2018 08 02.
Artículo en Inglés | MEDLINE | ID: mdl-30072750

RESUMEN

Increasing evidence suggests that pathological hallmarks of chronic degenerative syndromes progressively spread among interconnected brain areas in a disease-specific stereotyped pattern. Functional brain imaging from patients affected by various neurological syndromes such as traumatic brain injury and stroke indicates that the progression of such diseases follows functional connections, rather than simply spreading to structurally adjacent areas. Indeed, initial damage to a given brain area was shown to disrupt the communication in related brain networks. Using cortico-striatal neuronal networks reconstructed in a microfluidic environment, we investigated the role of glutamate signaling in activity-dependent neuronal survival and trans-synaptic degeneration processes. Using a variety of neuronal insults applied on cortical neurons, we demonstrate that acute injuries such as axonal trauma, focal ischemia, or alteration of neuronal rhythms, lead to glutamate-dependent striatal neuron dysfunction. Interestingly, focal pro-oxidant insults or chronic alteration of spontaneous cortical rhythms provoked dysfunction of distant striatal neurons through abnormal glutamate GluN2B-NMDAR-mediated signaling at cortico-striatal synapses. These results indicate that focal alteration of cortical functions can initiate spreading of dysfunction along neuronal pathways in the brain, reminiscent of diaschisis-like processes.


Asunto(s)
Lesiones Traumáticas del Encéfalo/metabolismo , Cuerpo Estriado/metabolismo , Ácido Glutámico/metabolismo , Red Nerviosa/metabolismo , Sinapsis/metabolismo , Transmisión Sináptica , Animales , Lesiones Traumáticas del Encéfalo/patología , Cuerpo Estriado/patología , Ratones , Red Nerviosa/patología , Sinapsis/patología
8.
Exp Gerontol ; 42(10): 951-62, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17596899

RESUMEN

In Alzheimer's disease there is an increased production of the toxic beta-amyloid peptides (Abeta), especially the longer forms such as Abeta(1-42). Using the patch-clamp technique we have studied the contribution of early pro-inflammatory processes to the acute effects of 1 microM Abeta(1-42) on the parallel fiber EPSC (PF-EPSC) of Purkinje cells in cerebellar slices. Abeta(1-42) induces a decrease in the PF-EPSC amplitude. This decrease is accompanied by a decrease in the frequency and amplitude of the miniature EPSCs, suggesting that Abeta acts at both pre- and post-synaptic sites. In the presence of L-NAME, a nitric oxide synthase inhibitor, the effects of Abeta were partially blocked. The frequency of mEPSCs was unchanged while Abeta still reduced the mEPSCs amplitude. The anti-inflammatory agent flurbiprofen blocked the depressant action of Abeta on the mEPSCs amplitude but not its effect on mEPSCs frequency. Both a p38 inhibitor (SB203580) and a JNK inhibitor (SP600125) reverse the effects of Abeta as an increase in the mEPSCs frequency and amplitude was observed. This study provides evidence that the Abeta-induced depression of the PF-EPSCs was mediated via an activation of JNK and p38 and by the action of NO and raises the possibility of the involvement of an early pro-inflammatory process.


Asunto(s)
Péptidos beta-Amiloides/farmacología , Inflamación/fisiopatología , Fragmentos de Péptidos/farmacología , Células de Purkinje/efectos de los fármacos , Péptidos beta-Amiloides/antagonistas & inhibidores , Animales , Antiinflamatorios no Esteroideos/farmacología , Inhibidores Enzimáticos/farmacología , Potenciales Postsinápticos Excitadores/efectos de los fármacos , Flurbiprofeno/farmacología , Ácido Glutámico/metabolismo , Ratones , Ratones Endogámicos C57BL , NG-Nitroarginina Metil Éster/farmacología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/fisiología , Técnicas de Placa-Clamp , Fragmentos de Péptidos/antagonistas & inhibidores , Células de Purkinje/fisiología , Receptores Nicotínicos/efectos de los fármacos , Receptores Nicotínicos/fisiología , Transducción de Señal , Sinapsis/efectos de los fármacos , Sinapsis/fisiología , Técnicas de Cultivo de Tejidos , Receptor Nicotínico de Acetilcolina alfa 7
9.
Brain Res Mol Brain Res ; 142(2): 97-106, 2005 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-16290312

RESUMEN

Current understanding of IGF-I-mediated neuroprotection implies the activation of phosphatidylinositol-3-kinase (PI-3K), which leads to the activation of Akt/Protein Kinase B. In non-neuronal cells, Akt phosphorylates and activates the transcription factor CREB, implicated in the transcription of the anti-apoptotic bcl-2 gene. This paper further analyses the anti-apoptotic IGF-I action in neurons. We show that IGF-I protects cortical neurons against ceramide-induced apoptosis. Ceramide decreases Akt phosphorylation during apoptotic process whereas a simultaneous treatment with IGF-I increases Akt phosphorylation. Analysis of the signal transduction pathways revealed that IGF-I induces CREB phosphorylation via PI-3K and ERK, whereas simultaneous ceramide and IGF-I treatment decreases CREB phosphorylation. Although an overexpression of Bcl-2 protects cortical neurons against ceramide-induced apoptosis, our data indicate that the Bcl-2 protein level is not modulated during IGF-I, ceramide and/or LY294002 treatment. In consequence, we demonstrated that IGF protects neurons against ceramide-induced apoptosis and that IGF-I protection involves the PI-3K/Akt and ERK pathways; this protection may be independent of CREB and Bcl-2.


Asunto(s)
Apoptosis/efectos de los fármacos , Corteza Cerebral/citología , Factor I del Crecimiento Similar a la Insulina/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neuronas/efectos de los fármacos , Fosfatidilinositol 3-Quinasas/metabolismo , Animales , Western Blotting/métodos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Ceramidas/toxicidad , Cromonas/farmacología , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/fisiología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Embrión de Mamíferos , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Genes bcl-2/fisiología , Proteínas Fluorescentes Verdes/biosíntesis , Inmunohistoquímica/métodos , Ratones , Ratones Transgénicos , Morfolinas/farmacología , Fosforilación/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Factores de Tiempo , Transfección/métodos
10.
ACS Chem Neurosci ; 6(3): 393-7, 2015 Mar 18.
Artículo en Inglés | MEDLINE | ID: mdl-25587803

RESUMEN

Intracranial hemorrhage, whether due to traumatic brain injury or ruptured cerebral aneurysm, is characterized by major neurological damage and a high mortality rate. Apart from cerebral vasospasm and mass effect, brain injury results from the release of unclotted blood that contacts neurons causing calcic stress. The combination of memantine with vitamin D, a neurosteroid hormone, may prevent blood neurotoxicity. Our purpose was to examine the potential protective effects of memantine + vitamin D against lysed or clotted blood in cortical neuronal cultures. We provide the first evidence that cortical axons in contact with lysed blood degenerate less after exposure to lysed blood in microfluidic neuronal cultures enriched with both memantine and vitamin D compared to control medium and cultures enriched with only memantine or only vitamin D. The reported synergistic neuroprotective effect of memantine + vitamin D, the combination originating an effect stronger than the sum, strongly encourages using both drugs following intracranial hemorrhage.


Asunto(s)
Axones/efectos de los fármacos , Memantina/farmacología , Degeneración Nerviosa/prevención & control , Neuronas/citología , Fármacos Neuroprotectores/farmacología , Vitamina D/farmacología , Animales , Células Sanguíneas/citología , Coagulación Sanguínea , Fraccionamiento Celular , Células Cultivadas , Corteza Cerebral/citología , Sinergismo Farmacológico , Embrión de Mamíferos , Dispositivos Laboratorio en un Chip , Ratones
11.
Neurobiol Aging ; 36(6): 2043-52, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25862419

RESUMEN

Amyloid-ß (Aß) oligomers are the suspected culprit as initiators of Alzheimer's disease (AD). However, their diffusion in the brain remains unknown. Here, we studied Aß oligomers' dissemination and evaluated their in vivo toxicity. Wild-type mice were injected with 50 pmol of synthetic Aß oligomers (of different size) in the hippocampus. Oligomers diffused largely in the brain as soon as 1 hour and up to 7 days after injection. A transient encephalopathy with memory impairment was induced by this unique injection. The immunoreactivity of the postsynaptic marker PSD95 was diffusely decreased. Similar results (both on memory and PSD95 immunoreactivity) were obtained with delipidated and high molecular weight oligomers (>50 kDa) but not with smaller assemblies. Tau hyperphosphorylation was observed in the oligomer-injected brains. Finally, fos immunostaining was increased in Aß-derived diffusible ligands-injected mice, suggesting neuronal hyperactivity. Rapid and widespread diffusion of Aß oligomers was demonstrated in vivo and associated with decreased synaptic markers and memory deficits which gives new insight to the pathogenicity of Aß.


Asunto(s)
Amnesia/inducido químicamente , Péptidos beta-Amiloides/metabolismo , Péptidos beta-Amiloides/toxicidad , Encefalopatías/inducido químicamente , Enfermedad Aguda , Enfermedad de Alzheimer/etiología , Amnesia/metabolismo , Péptidos beta-Amiloides/administración & dosificación , Animales , Transporte Biológico , Biopolímeros , Encéfalo/metabolismo , Encefalopatías/metabolismo , Difusión , Homólogo 4 de la Proteína Discs Large , Guanilato-Quinasas/metabolismo , Hipocampo , Inyecciones , Masculino , Proteínas de la Membrana/metabolismo , Ratones Endogámicos C57BL , Peso Molecular , Fosforilación , Sinapsis/efectos de los fármacos , Factores de Tiempo , Proteínas tau/metabolismo
12.
Mol Cell Endocrinol ; 186(1): 1-5, 2002 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-11850116

RESUMEN

The homozygous mutant mouse staggerer (RORa(sg)/RORa(sg)), was initially described as ataxic, due to the presence of massive neurodegeneration in the cerebellum [Science 136 (1962) 610]. The identification of the widely expressed Retinoic acid receptor-related Orphan Receptor, NR1F1 (RORalpha) gene as the site of mutation in the staggerer mouse has led to great progress in understanding the molecular basis of its phenotype in recent years [Nature 379 (1996) 736]. RORalpha is a transcription factor, belonging to the nuclear receptor superfamily, for which no natural ligand has yet been identified. Mice engineered for the disruption of the gene encoding RORalpha display the same cerebellar atrophic phenotype as the staggerer mouse [Proc. Natl. Acad. Sci. USA 95 (1998) 3960]. More recently, it has been shown that the mutation is semi-dominant, as heterozygous animals display an increased loss of Purkinje cells with age. Furthermore, a number of additional phenotypes outside the nervous system have recently been identified. These include a greater susceptibility to atherosclerosis [Circulation 15 (1998) 2738], immunodeficiencies linked to the overexpression of inflammatory cytokines [J. Neurochem. 58 (1992) 192], abnormalities in the formation and maintenance of bone tissue [Proc. Natl. Acad. Sci. USA 97 (2000) 9197] and changes in muscle differentiation [Nucleic Acids Res. 27 (1999) 411]. Thus, RORalpha has been directly linked to a number of age-related pathologies of great medical interest.


Asunto(s)
Encéfalo/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Transactivadores/metabolismo , Factores de Edad , Animales , Ratones , Ratones Mutantes Neurológicos , Modelos Animales , Mutación , Proteínas del Tejido Nervioso/genética , Miembro 1 del Grupo F de la Subfamilia 1 de Receptores Nucleares , Fenotipo , Receptores Citoplasmáticos y Nucleares/genética , Transactivadores/genética
13.
Brain Res Mol Brain Res ; 111(1-2): 52-60, 2003 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-12654505

RESUMEN

PC12 cells that are differentiated with NGF and cAMP become totally dependent on these factors for their survival, unlike those that are differentiated with NGF alone. We have asked whether the MAP Kinases, ERKs, JNKs and p38s play a role in the cell death induced by withdrawal of trophic factors on NGF- and NGF/cAMP-differentiated PC12 cells. By Western-blot analyses with antibodies directed against the activated forms of these kinases, we show that when the trophic factors were withdrawn, ERK phosphorylation was reduced to very low levels within 1 h in both cases. Changes in the other enzymes were observed only in the NGF/cAMP-differentiated cells, in which the JNK phosphorylation increased about 160% by 6 h and that of p38 increased linearly to at least 18-fold throughout the cell death process. The increases in p38 and JNK phosphorylation were implicated in the death of the cells, since the p38 inhibitor PD169316 and the JNK inhibitor SP600125 were protective. These results demonstrate that the state of differentiation of PC12 cells, a model for the differentiation of sympathetic neurons, determines their vulnerability to cell death by modifying the state of phosphorylation and the regulation of specific kinases implicated in signal transduction pathways that are responsible for the survival or the death of these cells.


Asunto(s)
Muerte Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Sistema de Señalización de MAP Quinasas/fisiología , Factores de Crecimiento Nervioso/deficiencia , Neuronas/enzimología , Sistema Nervioso Simpático/embriología , Sistema Nervioso Simpático/enzimología , Animales , Muerte Celular/genética , Diferenciación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , AMP Cíclico/deficiencia , AMP Cíclico/genética , Regulación hacia Abajo/efectos de los fármacos , Regulación hacia Abajo/fisiología , Inhibidores Enzimáticos/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteína Quinasa 8 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Factor de Crecimiento Nervioso/deficiencia , Factor de Crecimiento Nervioso/genética , Factores de Crecimiento Nervioso/farmacología , Neuronas/efectos de los fármacos , Células PC12 , Fosforilación/efectos de los fármacos , Ratas , Sistema Nervioso Simpático/efectos de los fármacos , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología , Proteínas Quinasas p38 Activadas por Mitógenos
14.
Neurobiol Aging ; 35(2): 331-5, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24011542

RESUMEN

The currently available drugs for treatment of Alzheimer's disease are symptomatic and only temporarily slow down the natural history of the disease process. Recently, its has been proposed that the combination of memantine with vitamin D, a neurosteroid hormone, may prevent amyloid-beta and glutamate neurotoxicity. Here, our purpose was to examine the potential protective effects of memantine and vitamin D against amyloid-beta peptide and glutamate toxicity in cortical neuronal cultures. We provide the first evidence that cortical axons degenerate less after exposure to amyloid-beta peptide or glutamate in microfluidic neuronal cultures enriched with memantine plus vitamin D compared to control medium and cultures enriched with only memantine or only vitamin D. The reported synergistic neuroprotective effect of memantine plus vitamin D -the combination originating an effect stronger than the sum- corroborate previous clinical finding that Alzheimer's disease patients using this drug combination have improved cognition. This finding reinforces the pharmacological potential of a new drug combining memantine plus vitamin D for the treatment or the prevention of Alzheimer's disease.


Asunto(s)
Péptidos beta-Amiloides/toxicidad , Axones/patología , Antagonistas de Aminoácidos Excitadores/farmacología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Ácido Glutámico/toxicidad , Memantina/farmacología , Memantina/uso terapéutico , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/prevención & control , Fármacos Neuroprotectores , Vitamina D/farmacología , Vitamina D/uso terapéutico , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/prevención & control , Péptidos beta-Amiloides/antagonistas & inhibidores , Animales , Células Cultivadas , Sinergismo Farmacológico , Quimioterapia Combinada , Ratones
15.
Acta Neuropathol Commun ; 2: 145, 2014 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-25253021

RESUMEN

INTRODUCTION: Recent histopathological studies have shown that neurodegenerative processes in Alzheimer's and Parkinson's Disease develop along neuronal networks and that hallmarks could propagate trans-synaptically through neuronal pathways. The underlying molecular mechanisms are still unknown, and investigations have been impeded by the complexity of brain connectivity and the need for experimental models allowing a fine manipulation of the local microenvironment at the subcellular level. RESULTS: In this study, we have grown primary cortical mouse neurons in microfluidic (µFD) devices to separate soma from axonal projections in fluidically isolated microenvironments, and applied ß-amyloid (Aß) peptides locally to the different cellular compartments. We observed that Aß application to the somato-dendritic compartment triggers a "dying-back" process, involving caspase and NAD(+) signalling pathways, whereas exposure of the axonal/distal compartment to Aß deposits did not induce axonal degeneration. In contrast, co-treatment with somatic sub-toxic glutamate and axonal Aß peptide triggered axonal degeneration. To study the consequences of such subcellular/local Aß stress at the network level we developed new µFD multi-chamber devices containing funnel-shaped micro-channels which force unidirectional axon growth and used them to recreate in vitro an oriented cortico-hippocampal pathway. Aß application to the cortical somato-dendritic chamber leads to a rapid cortical pre-synaptic loss. This happens concomitantly with a post-synaptic hippocampal tau-phosphorylation which could be prevented by the NMDA-receptor antagonist, MK-801, before any sign of axonal and somato-dendritic cortical alteration. CONCLUSION: Thanks to µFD-based reconstructed neuronal networks we evaluated the distant effects of local Aß stress on neuronal subcompartments and networks. Our data indicates that distant neurotransmission modifications actively take part in the early steps of the abnormal mechanisms leading to pathology progression independently of local Aß production. This offers new tools to decipher mechanisms underlying Braak's staging. Our data suggests that local Aß can play a role in remote tauopathy by distant disturbance of neurotransmission, providing a putative mechanism underlying the spatiotemporal appearance of pretangles.


Asunto(s)
Péptidos beta-Amiloides/toxicidad , Corteza Cerebral/patología , Red Nerviosa/patología , Sinapsis/patología , Animales , Axones/efectos de los fármacos , Axones/metabolismo , Axones/patología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Ratones , Técnicas Analíticas Microfluídicas/métodos , Red Nerviosa/efectos de los fármacos , Red Nerviosa/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Fosforilación , Cultivo Primario de Células/métodos , Sinapsis/efectos de los fármacos , Sinapsis/metabolismo , Proteínas tau/metabolismo
16.
PLoS One ; 8(8): e71103, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23976987

RESUMEN

Chronic neurodegenerative syndromes such as Alzheimer's and Parkinson's diseases, or acute syndromes such as ischemic stroke or traumatic brain injuries are characterized by early synaptic collapse which precedes axonal and neuronal cell body degeneration and promotes early cognitive impairment in patients. Until now, neuroprotective strategies have failed to impede the progression of neurodegenerative syndromes. Drugs preventing the loss of cell body do not prevent the cognitive decline, probably because they lack synapto-protective effects. The absence of physiologically realistic neuronal network models which can be easily handled has hindered the development of synapto-protective drugs suitable for therapies. Here we describe a new microfluidic platform which makes it possible to study the consequences of axonal trauma of reconstructed oriented mouse neuronal networks. Each neuronal population and sub-compartment can be chemically addressed individually. The somatic, mid axon, presynaptic and postsynaptic effects of local pathological stresses or putative protective molecules can thus be evaluated with the help of this versatile "brain on chip" platform. We show that presynaptic loss is the earliest event observed following axotomy of cortical fibers, before any sign of axonal fragmentation or post-synaptic spine alteration. This platform can be used to screen and evaluate the synapto-protective potential of several drugs. For instance, NAD⁺ and the Rho-kinase inhibitor Y27632 can efficiently prevent synaptic disconnection, whereas the broad-spectrum caspase inhibitor zVAD-fmk and the stilbenoid resveratrol do not prevent presynaptic degeneration. Hence, this platform is a promising tool for fundamental research in the field of developmental and neurodegenerative neurosciences, and also offers the opportunity to set up pharmacological screening of axon-protective and synapto-protective drugs.


Asunto(s)
Amidas/farmacología , Inhibidores Enzimáticos/farmacología , Microfluídica/métodos , NAD/farmacología , Red Nerviosa/efectos de los fármacos , Piridinas/farmacología , Sinapsis/efectos de los fármacos , Clorometilcetonas de Aminoácidos/farmacología , Animales , Axones/efectos de los fármacos , Axones/fisiología , Axones/ultraestructura , Dendritas/efectos de los fármacos , Dendritas/fisiología , Dendritas/ultraestructura , Embrión de Mamíferos , Ratones , Microfluídica/instrumentación , Microscopía Fluorescente , Modelos Neurológicos , Red Nerviosa/fisiología , Enfermedades Neurodegenerativas/patología , Enfermedades Neurodegenerativas/prevención & control , Cultivo Primario de Células , Resveratrol , Estilbenos/farmacología , Sinapsis/fisiología , Sinapsis/ultraestructura
17.
Neurotox Res ; 19(1): 149-61, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-20162389

RESUMEN

Degeneration of central axons may occur following injury or due to various diseases and it involves complex molecular mechanisms that need to be elucidated. Existing in vitro axotomy models are difficult to perform, and they provide limited information on the localization of events along the axon. We present here a novel experimental model system, based on microfluidic isolation, which consists of three distinct compartments, interconnected by parallel microchannels allowing axon outgrowth. Neurons cultured in one compartment successfully elongated their axons to cross a short central compartment and invade the outermost compartment. This design provides an interesting model system for studying axonal degeneration and death mechanisms, with a previously impossible spatial and temporal control on specific molecular pathways. We provide a proof-of-concept of the system by reporting its application to a well-characterized experimental paradigm, axotomy-induced Wallerian degeneration in primary central neurons. Using this model, we applied localized central axotomy by a brief, isolated flux of detergent. We report that mouse embryonic cortical neurons exhibit rapid Wallerian-like distal degeneration but no somatic death following central axotomy. Distal axons show progressive degeneration leading to axonal beading and cytoskeletal fragmentation within a few hours after axotomy. Degeneration is asynchronous, reminiscent of in vivo Wallerian degeneration. Axonal cytoskeletal fragmentation is significantly delayed with nicotinamide adenine dinucleotide pretreatment, but it does not change when distal calpain or caspase activity is inhibited. These findings, consistent with previous experiments in vivo, confirm the power and biological relevance of this microfluidic architecture.


Asunto(s)
Técnicas de Cultivo de Célula/métodos , Corteza Cerebral/patología , Microfluídica/métodos , Neuronas/patología , Degeneración Walleriana/patología , Animales , Axotomía/métodos , Sistema Nervioso Central/citología , Sistema Nervioso Central/patología , Corteza Cerebral/citología , Corteza Cerebral/embriología , Ratones , Neuronas/citología
18.
Lab Chip ; 11(21): 3663-73, 2011 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-21922081

RESUMEN

Various experimental models are used to study brain development and degeneration. They range from whole animal models, which preserve anatomical structures but strongly limit investigations at the cellular level, to dissociated cell culture systems that allow detailed observation of cell phenotypes but lack the highly ordered physiological neuron connection architecture. We describe here a platform comprising independent cell culture chambers separated by an array of "axonal diodes". This array involves asymmetric micro-channels, imposing unidirectional axon connectivity with 97% selectivity. It allows the construction of complex, oriented neuronal networks not feasible with earlier platforms. Different neuronal subtypes could be co-cultivated for weeks, and sequential seeding of different cell populations reproduced physiological network development. To illustrate possible applications, we created and characterized a cortico-striatal oriented network. Functional synaptic connections were established. The activation of striatal differentiation by cortical axons, and the synchronization of neural activity were demonstrated. Each neuronal population and subcompartment could be chemically addressed individually. The directionality of neural pathways being a key feature of the nervous system organization, the axon diode concept brings in a paradigmatic change in neuronal culture platforms, with potential applications for studying neuronal development, synaptic transmission and neurodegenerative disorder such as Alzheimer and Parkinson diseases at the sub-cellular, cellular and network levels.


Asunto(s)
Axones/fisiología , Técnicas Analíticas Microfluídicas , Red Nerviosa/citología , Neuronas/citología , Compuestos de Anilina/química , Animales , Calcio/metabolismo , Diferenciación Celular , Células Cultivadas , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Ratones , Ratones Transgénicos , Red Nerviosa/metabolismo , Red Nerviosa/fisiología , Neuronas/metabolismo , Xantenos/química
19.
Biomicrofluidics ; 5(2): 24102, 2011 Apr 14.
Artículo en Inglés | MEDLINE | ID: mdl-21559239

RESUMEN

A broad range of microfluidic applications, ranging from cell culture to protein crystallization, requires multilevel devices with different heights and feature sizes (from micrometers to millimeters). While state-of-the-art direct-writing techniques have been developed for creating complex three-dimensional shapes, replication molding from a multilevel template is still the preferred method for fast prototyping of microfluidic devices in the laboratory. Here, we report on a "dry and wet hybrid" technique to fabricate multilevel replication molds by combining SU-8 lithography with a dry film resist (Ordyl). We show that the two lithography protocols are chemically compatible with each other. Finally, we demonstrate the hybrid technique in two different microfluidic applications: (1) a neuron culture device with compartmentalization of different elements of a neuron and (2) a two-phase (gas-liquid) global micromixer for fast mixing of a small amount of a viscous liquid into a larger volume of a less viscous liquid.

20.
Neural Dev ; 5: 18, 2010 Jul 27.
Artículo en Inglés | MEDLINE | ID: mdl-20663205

RESUMEN

BACKGROUND: The active form (T3) of thyroid hormone (TH) controls critical aspects of cerebellar development, such as migration of postmitotic neurons and terminal dendritic differentiation of Purkinje cells. The effects of T3 on early dendritic differentiation are poorly understood. RESULTS: In this study, we have analyzed the influence of T3 on the progression of the early steps of Purkinje cell dendritic differentiation in postnatal day 0 organotypic cerebellar cultures. These steps include, successively, regression of immature neuritic processes, a stellate cell stage, and the extension of several long and mature perisomatic protrusions before the growth of the ultimate dendritic tree. We also studied the involvement of RORalpha, a nuclear receptor controlling early Purkinje cell dendritic differentiation. We show that T3 treatment leads to an accelerated progression of the early steps of dendritic differentiation in culture, together with an increased expression of RORalpha (mRNA and protein) in both Purkinje cells and interneurons. Finally, we show that T3 failed to promote early dendritic differentiation in staggerer RORalpha-deficient Purkinje cells. CONCLUSIONS: Our results demonstrate that T3 action on the early Purkinje cell dendritic differentiation process is mediated by RORalpha.


Asunto(s)
Diferenciación Celular/fisiología , Cerebelo/embriología , Dendritas/metabolismo , Miembro 1 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Células de Purkinje/metabolismo , Triyodotironina/metabolismo , Animales , Diferenciación Celular/efectos de los fármacos , Forma de la Célula/efectos de los fármacos , Forma de la Célula/genética , Cerebelo/citología , Dendritas/efectos de los fármacos , Dendritas/ultraestructura , Interneuronas/citología , Interneuronas/efectos de los fármacos , Interneuronas/metabolismo , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes Neurológicos , Neuritas/efectos de los fármacos , Neuritas/metabolismo , Neuritas/ultraestructura , Neurogénesis/efectos de los fármacos , Neurogénesis/fisiología , Miembro 1 del Grupo F de la Subfamilia 1 de Receptores Nucleares/efectos de los fármacos , Miembro 1 del Grupo F de la Subfamilia 1 de Receptores Nucleares/genética , Técnicas de Cultivo de Órganos , Células de Purkinje/citología , Células de Purkinje/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/genética , Triyodotironina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA